Calcium phosphate coated core-shell protein nanocarriers: Robust stability, controlled release and enhanced anticancer activity for curcumin delivery by Wu, Q. et al.
Wu, Q., Gao, H., Vriesekoop, F., Liu, Z., He, J. and Liang, H. 2020. Calcium phosphate coated core-
shell protein nanocarriers: robust stability, controlled release and enhanced anticancer activity for 
curcumin delivery. Materials Science and Engineering: C. 
19 May 2020 
 
Calcium phosphate coated core-
shell protein nanocarriers: robust 
stability, controlled release and 
enhanced anticancer activity for 
curcumin delivery  
 
by Wu, Q., Gao, H., Vriesekoop, F., Liu, Z., He, J. and 
Liang, H. 
 
Copyright, publisher and additional Information: This is the author accepted manuscript. 
The final published version (version of record) is available online via Elsevier. 



















• NaCas@CaP nanodelivery system has nano-size and core-shell structure. 
 
• The mechanism of encapsulation was characterized and analyzed. 
 
• The stability of the encapsulated Cur was significantly improved. 
 
• The pH-responsive release around the cancer cell was achieved. 
 
• The encapsulated Cur existed better cellular anti-oxidant and anti-cancer ability. 
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16 ABSTRACT: Composite protein and inorganic nanodelivery systems can realise a 
 
17 pH-responsive release and effectively improve the  stability and anti-cancer 
 
18 proliferative activity of hydrophobic molecules. In this study, a novel core-shell 
19 structure of NaCas (Sodium Caseinate)@CaP (Calcium  Phosphate) as a nanodelivery 
 
20 system  with NaCas  as  the  core  for  increasing  solubility  and  CaP  as the  shell for 
 
21 enhanced stability was built. By using Cur (Curcumin) as a model bioactive molecule, 
 
22 (Cur@NaCas)@CaP nanoparticles  (NPs) demonstrated  a uniform size distribution of 
 
23 150-200 nm with a distinct nano-composite structure. After exposure to 80 °C for  2 h, 
 
24 the  NaCas@CaP  loaded   Cur  still  retained   80%  stability   while   under  the same 
 
25 conditions only 12 % of free Cur remained  intact. UV-light stability  was remarkably 
 
26 enhanced  8.56  fold  by  the protection  of the core-shell  structure.  More importantly, 
 
27 pH-responsive release was achieved owing to the CaP surface coating. The 
 
28 encapsulated  Cur  by  NaCas@CaP NPs exhibited  an enhanced  cellular anti-oxidant 
 
29 activity  (CAA)  based  on  MGC-803  cell  monolayer  models.  The  confocal  laser- 
 
30 scanning microscopy (CLSM) images and cancer-cell-proliferation assay illustrated 
 
31 that (Cur@NaCas)@CaP NPs showed  significantly  improvements  of cellular uptake 
 
32 and  anti-cancer  activity  against  A549 cancer  cells than free Cur. These novel core- 
 
33 shell   NaCas@CaP   NPs   are   very   promising   for   intensifying   the  stability and 
 




36 Key words: Nanodelivery, Sodium caseinate, Calcium phosphate, Curcumin, Anti- 
 





40 Natural self-assembled delivery systems are nanodelivery systems formed by the 
 
41 self-assembly  of  natural  biomaterials  with  nanostructures.[1, 2] These biomaterials 
 
42 can spontaneously  form  regular  shapes, such  as spheres,  cylinders,  lamellae, etc.,  by 
 
43 relatively  weak  non-covalent  interactions  at concentrations well above their critical 
 
44 micelle concentration.[3-5] These systems are mainly used to encapsulate, protect and 
 
45 transport  functional  active  substances  because  of their  enhanced  permeability and 
 
46 retention  effect.[6,  7] The enhanced  permeability  and  retention  effect  refers  to the 
 
47 notion that certain macromolecules and nanoparticles accumulate inside tumor tissues 
 
48 at   greater concentrations  compared to  non-tumor tissues.[8] Compared with 
 
49 traditional  embedding  technologies,  natural  self-assembled  delivery  systems  have 
 
50 size-related  effects, due to the relatively  random  nature of the self-assembly  process 
 
51 which results in a heterogeneous  range of surfaces  and  sized  particles. Furthermore, 
 
52 natural   self-assembled  delivery   systems  also  have  different   in  vivo distribution 
 
53 specificity with regards to the targeted delivery of drugs and nutritional 
 
54 compounds.[9, 10] Moreover, biodegradable  self-assembled delivery systems improve 
 
55 the  bioavailability of  guest  molecules,  and  can  achieve  a controlled  and sustained 
 
56 release,  and  facilitate  targeted  delivery  of  bioactive  compounds.[11]  Due  to their 
 
57 biodegradability, natural  self-assembled  delivery  systems pose minimal cytotoxicity, 
 
58 are renewable and have an abundant availability, a high drug binding capacity, and a 
 
59 significant  uptake  by target cells, protein-based  delivery  systems, including zein,[11] 
 
60 soy   protein   isolate,[12]  sodium   caseinate[13]   and   ferritins,[14]  have   received 
 
61 increasing attention as natural self-assembled delivery systems. 
62 Sodium caseinates (NaCas) is a widely used food additive derived from milk. With 
 
63 distinct hydrophobic and hydrophilic domains, NaCas can self-assemble into a  stable 
 
64 micellar structure in aqueous solution, especially when its concentration is higher than 
 
65 the its critical  micelle  concentration.[13] Due  to  its excellent  biocompatibility and 
 
66 biodegradability,  and  limited  immunogenicity,  NaCas  is  regularly  employed  as a 
 
67 unique natural self-assembled nanodelivery  material  in  biological  applications.[15] 
 
68 NaCas  has  been  used  to  enhance  the  solubility,  stability   and   bioavailability  of 
 
69 otherwise insoluble natural compounds, especially those with considerable  biological 
 
70 activity, such as some vitamins and their precursors, [16-18] and antioxidants.[19] 
 
71 Although the deployment of NaCas is a strategic improvement in the delivery of 
 
72 otherwise recalcitrantly soluble bioactive molecules, the long-term stability of NaCas 
 
73 nanoparticles  (NPs)  remains  a major  obstacle  for their  successful  applications  as 
 
74 delivery  vehicles.  The  structural  integrity  of  NaCas  is readily  compromised  as a 
 
75 consequence   of  changes   in  pH,   ionic   strength,   water   activity,   temperature or 
 
76 pressure,[20]  which  causes  an  imbalance   between  hydrophobic  and electrostatic 
 
77 interactions.[21,   22]   Various   strategies for  improving the stability of NaCas 
 
78 nanostructures  are  emerging.   Organic  materials   such  as  pectin,[23] chitosan,[24] 
 
79 alginates,[25] and combinations  thereof [26] have been used  to stabilize NaCas NPs. 
 
80 However, even these nanocarriers still fall short of providing sufficient 
 
81 physicochemical stability and often require complicated  assembly  processes.[27, 28] 
 
82 Therefore, a stable nanoscale  NaCas  system  with a simple  assembly  method for its 
 
83 synthesis is urgently needed for the delivery of sensitive molecules. 
84 Hybridization of organic and inorganic carriers can confer nanomaterials with new 
 
85 stability  related  properties  not normally  associated  with the individual carriers.[29, 
 
86 30] Calcium phosphate (CaP) NPs have good adsorption capacity and pH-responsive 
 
87 release  characterization  for  both  proteins  and  drugs.[31-33]  CaP  NPs  can deliver 
 
88 diagnostic   and   therapeutic   agents   with  minimal   toxicity   for  the  detection and 
 
89 treatment of various diseases including cancer.[34]In order to improve the stability  of 
 
90 NaCas particles, we chose CaP to provide a secondary coating and as such address the 
 
91 premature  release  from  compounds  encapsulated   by  NaCas.[13]  We  constructed 
 
92 hybrid  NaCas-CaP  NPs  (NaCas@CaP  NPs)  with  a  stable  core-shell  structure by 
 
93 means of a simple,  one-pot method  under  mild  conditions  using curcumin  (Cur),  a 
 
94 natural  anti-cancer  biomolecule,  as a model  guest  molecule  (Scheme  1).  Cur  was 
 
95 encapsulated  into the core  of NaCas  micellar  particles  by  hydrophobic interactions 
 
96 during  the self-assembly  process  of dissociated  NaCas, yielding  Cur@NaCas NPs. 
 
97 The Cur@NaCas surface  was simultaneously coated  with  CaP as a stable  shell. The 
 
98 formation and conformation of the encapsulated-core-and-shell NPs were 
 
99 characterized by various means. The stability and in vitro releasing of 
 
100 (Cur@NaCas)@CaP NPs at physiological  pH and the pH encountered  in cancer cells 
 
101 were  examined.  In  addition,  the  cellular   uptake  ability,  the  cellular  anti-oxidant 
 
102 activity  and in vitro cell proliferation  assay  of the inclusion  complexes  were tested 
 
103 and compared with free Cur. Our results indicated that the NaCas@CaP NPs with 
 
104 high efficiency  and  stability  are a novel  nanoplatform  for cancer  therapy  and  free 
105 radical scavenging in vivo. Furthermore , the NPs have universality for hydrophobic 
 

















109 Scheme 1 Schematic mechanism of encapsulation and cell-uptake of NaCas@CaP 
 




112 2 Material and methods 
 
113 2.1 Materials and Cell Culture 
 
114 Curcumin (Cur, 98 %), sodium caseinate (NaCas) were purchased from Macklin 
 
115 Biochemical Co., Ltd, (Shanghai , China). 2,2-azobis (2-amidinopropane) 
 
116 dihydrochloride (ABAP), 2,7-dichlorodi-hydrofluorescein  diacetate (DCFH-DA), and 
 
117 Propidium Iodide (PI) were obtained from Sigma-Aldrich, (St Louis, MO, USA). Cell 
 
118 Counting Kit-8 (CCK-8) was obtained from Dojindo Laboratories (Tokyo, Japan). All 
 
119 other chemicals (analytical grade) were purchased from Beijing Chemical Works 
 
120 (Beijing, China), and were applied without further purification. Human gastric cancer 
 
121 cells (MGC803)  and  human alveolar  basal epithelial  cancer cells (A549 cells) were 
 
122 obtained  from the Cell  Resource  Center, Peking  Union  Medical  College (Beijing, 
123 China), and cultured with DMEM supplemented with 10 % Fetal Bovine Serum and 
 
124 1 % P/S at 95+% RH with 5 % CO2 at 37 °C. 
 
 
125 2.2 Preparation of (Cur@NaCas)@CaP NPs 
 
126 Samples were prepared by rehydrating NaCas in 10 mM phosphate buffer solution 
 
127 (pH 7.4) at room temperature  (25 °C) with moderate stirring for 30 min to produce  a 
 
128 NaCas stock solution  at 1 mg/mL.  A Cur  stock  solution  of 500 µg/mL  in absolute 
 
129 ethyl alcohol was prepared. 200 µL of the Cur stock solution was vigorously mixed at 
 
130 600 rpm with 1 mL  NaCas solution  at room  temperature  for 2 h. The  successfully 
 
131 encapsulated  Cur (Cur@NaCas) was  separated  from  the  non-encapsulated Cur  by 
 
132 centrifugation at   290  g  for  10  min.  The   resultant   supernatant   containing   the 
 
133 Cur@NaCas  was  subjected   to  (i)  secondary   encapsulation,  (ii)  particle property 
 
134 characterization or (iii) freeze-drying to produce Cur@NaCas NPs for further study. 
 
135 Un-encapsulated Cur on the bottom was measured in order to calculate the drug 
 
136 loading efficiency (DLE). Free curcumin was determined by UV-vis at 428 nm. The 
 
137 DLE of Cur@NaCas was calculated according to following eq.(1): 
 
 
138  ( 
1) 
DLE( %) = 
total amount of added Cur - amount of Cur on the bottom 
total amount of added Cur 
x 100% 
 
139 To facilitate the secondary encapsulation, 20 µL calcium chloride (CaCb) solution 
 
140 (50 mM) was added to the Cur@NaCas NPs solution in PBS (10 mM, pH 7.4) to form 
 
141 (Cur@NaCas)@CaP NPs. The mixture was mixed using a vortex mixer (SCILOGEX 
 
142 MX-S) for 2 min and then allowed  to stand for 24 h. The precipitate was either  used 
 
143 for immediate particle property characterization  or it was freeze-dried to produce the 
144 (Cur@NaCas)@CaP NPs powders that were used for further study.  Un-encapsulated 
 
145 Cur@NaCas  on the supernatant  was measured  in order  to calculate  the  DLE.  The 
 
146 DLE of (Cur@NaCas)@CaP was calculated according to following eq.(2). 
 
 
147  (2) DLE = 
total amount of added Cur@N aCas - amount of Cur@N aCas in supernatant 




148 2.3 Characterization 
 
149 The various samples used and constructed in this study (NaCas, Cur@NaCas and 
150 (Cur@NaCas)@CaP)   were   investigated   using  transmission   emission microscopy 
151 (TEM,   Hitachi  HT7700,  Tokyo,  Japan)  and  scanning  electron  microscope  (SEM, 
152 Hitachi  S-4700,  Tokyo,  Japan).[35] The average size and  zeta-potential of free  Cur 
153 and the various inclusion complexes  were ascertained  using dynamic light scattering 
154 (DLS, Nano-ZS  2000, Malvern  Instruments, UK). The crystalline characterization of 
155 free   Cur   and   the   various   inclusion complexes was   facilitated using X-ray 
156 diffractometer (XRD,  D8 ADVANCE, Germany,  Bruker)  at a diffraction angle of 20 
157 ranging from 5° to 50° with a stepwise scan rate of 10°/min at 0.2° per step. The FT- 
158 IR spectra of freeze-dried  samples  were obtained  using  a fourier-transform infrared 
159 spectrometer  (FT-IR,  Nicolet  6700,  Madison,  WI, USA)  with  a scanning  range of 
 
160  4000 - 500 cm-•1 The fluorescence spectra for free Cur and encapsulated Cur were 
161 recorded  by  employing  a  fluorescence  spectrophotometer  (Hitachi  F7000, Tokyo, 
162 Japan)  at  an  excitation  wavelength  of  420  nm,  with  the  emission  spectra  being 
163 recorded  of  a range  from  440  - 650  nm  at a slit  width  of  5  nm.  Dispersions   of 
164 inclusion  complexes  were  prepared  in deionized  water.  Free Cur  was dissolved in 
165 ethanol or deionized water to the same final concentration as in the encapsulated Cur. 
 
 
166 2.4 In vitro stability of nano-encapsulated Cur 
 
167 The in vitro stability of free Cur and the various NPs was determined according to a 
168 previously reported method.[12] Following the various treatments, the samples were 
169 centrifuged and the ethanolic supernatant was analyzed by HPLC(Liquid column: C18 
 
170 (200  mmx 4.6  mm,  5µm);  Mobile  phase:  0.1%  phosphate  -  acetonitrile   (50:50); 
 
171 Detection  wavelength:  430  nm; Velocity  of flow: 1.0 ml/min ; 25°C;  Injection volume: 
172 20 µL). The initial data for all the cases was set as 100%. 
 
 
173 2.5 In vitro release of Cur 
 
17 4 The in vitro release of Cur from NaCas or NaCas@CaP NPs was established by a 
 
175 dialysis  protocol  according  to a  method  reported  elsewhere.[36] First,  Cur loaded 
 
176 inclusion complex were fully dispersed  in a release medium (PBS, pH 7.4 or pH 5.5) 
 
177 in a dialysis  bag (MWCO 3500Da), which was then put into a  dissolution  apparatus, 
 
178 and immersed  in 200 mL of the dissolution medium  with 1 ¾(w/v) Tween-80 under 
 
179 gentle stirring  at a rate of 100 rpm  at 37 °C. At various  time  intervals, an aliquot of 
 
180 the sample was extracted and analyzed to determine the release of Cur by HPLC. 
 
 
181 2.6 Cellular Uptake Measured by Confocal Laser Scanning Microscope. 
 
182 A549 cells (4x104 cells/well) were attached to a confocal laser dish over a 12 h 
 
183 period, after which the cells were washed once with PBS and treated with either free 
 
184 Cur or Cur-loaded NPs (2 mL, 5 µg/mL, in DMEM) and incubated at 37 °C, 5 % CO2 
 
185 for 6 h. Then the cells were washed twice with PBS to remove all extracellular Cur. A 
 
186 4 % paraformaldehyde solution was added to fix the cells (at room temperature for 30 
 
187 min), after which 200 µL PI was added to stain the cell nucleus for 15 min. Prior to 
 
188 imaging , all the cells samples were washed once more with PBS. The images of 
 
189 confocal   laser  scanning  microscope  (CLSM)  were  captured   by  exciting  Cur  at 442 
190 run, PI at 488 run, with emissions measured at 475 run and 630 run respectively. 
 
 
191 2.7 Cellular Antioxidant Activity 
 
192 Cellular antioxidant activity (CAA)was determined according to the method 
 
193 reported previously.[35] Briefly, MGC803 cells were seeded in 96-well plates with a 
 
194 concentration of 2.5 x  105  cells per milliliter and incubated for 24 h. Then the growth 
 
195 medium  was removed  and  replaced  with either 100 µL fresh medium  containing  2 
 
196 µg/mL  free Cur or Cur-loaded  NPs and  incubated  for another  24 h. After 24h, fresh 
 
197 medium  (100  µL)  containing  25  µM  DCFH-DA  was  added  into  each  well  and 
 
198 incubated for 1 h. Then, all wells were rinsed  with PBS before 100 µL fresh medium 
 
199 containing 600 µM ABAP was added into each well. A microplate reader employing 
 
200 an excitation wavelength of 485 run and an emission wavelength of 535 run was used 
 
201 to measure the fluorescent  intensity of samples, over an 1 h period  at 5 minutes 
 
202 intervals. The control  samples  were treated  with DCFH-DA  and  ABAP only, while 
 
203 the  blank samples  contained  cells treated  with DCFH-DA  only. The area  under the 
 
204 time-fluorescence intensity  curve can be obtained  by integration, and the antioxidant 
 




207 (3) CAA= 100 - (f SA/ f CA) x 100 
 
208 f SA represent the integral area of the fluorescence value-time curve by adding 
209 different concentrations of Cur; 
210 f CA represent the integral area of the blank group fluorescence value-time curve. 
211 2.8 In Vitro Cell Anti - proliferation Assay. 
 
 
212 A549 cells were seeded into 96-well microtiter plates at a density of 4000 cells per 
 
213 well  in  100  µL  of  medium.  After  24  h,  the  cells  were  treated   with  a  medium 
 
214 containing  DMSO-dissolved Cur, NaCas-encapsulated or NaCas@CaP-encapsulated 
 
215 Cur.  Other  cells  were  untreated  (negative  controls)  or  treated  only  with DMSO, 
 
216 NaCas   or   NaCas@CaP   NPs   at   the  concentrations  as  in   the  dispersions  with 
 
217 encapsulated curcumin  (positive  controls). After  72 h treatmen,t CCK-8 solution (20 
 
218 µL) was added to each well and then incubated for 1 h. The absorbance at 450 nm was 
 
219 measured  with  a  microplate   reader   (Bio-Tek  Instruments,  Winooski ,  VT). The 
 
220 normalized cell viability was obtained after normalizing the viability of a treatment by 
 
221 the viability  of  control  cells  treated  with  DMSO  only.  The  cell  viability  can be 
 
222 calculated using the following eq.(4): 
 
223 (4) Cell viability= (Atreated/AcontroD X 100% 
 
224 where Atreated and Acontrol are the absorbance of the wells with cells treated by Cur and 
 
225 the control, respectively.  The mean and standard  deviation from three-well replicates 
 




228 3. Results and discussion 
 
229 3.1 Preparation and Characterization of CaP coated Core-Shell nanoparticles 
 
230 (Cur@NaCas)@CaP NPs were prepared using the self-assembly and surface- 
 
231 coating method  outlined  above.  By  adjusting  the  concentration  of  NaCas  and the 
 
232 stirring   speed   during   the   encapsulation   access,   the  optimized   conditions were 
233 determined  as:  l mg/mL NaCas (Table S1), 600 rpm/min (Table S2), 2h (Table S3), 
 
234 achieving a DLE of 90.01±1.29 %. See the supplementary data for more in-depth data 
 
235 about the optimization of this methodology. 
 
236 After that, calcium ions as CaCh were added which interacted with the phosphate 
 
237 in PBS, which in tum allowed  the formation of a CaP coating on the surface ofNaCas 
 
238 protein   to  obtain   Cur@NaCas)@CaP.   The   DLE   of  (Cur@NaCas)@CaP under 
 
239 optimized conditions of CaP (Table S4) was 99.25±1.97 %. 
 
240 TEM was performed to identify the formation of core-shell structure, and the size 
 
241 distribution  of  particles  was  determined  by  DLS (Figure  lG).  The  native NaCas 
 
242 appeared  as uniform and  compact  spherical  structure  (Figure  lA) with an average 
 
243 size of 28 nm. The particle  size of Cur@NaCas NPs was slightly  larger  than that  of 
 
244 native  NaCas (Figure  1B) with an average  size of 32 nm. After  the application  of a 
 
245 Ca3(PO4) 2 coating, the formed particles in the range of 195-205 nm, with the TEM 
 
246 image (Figure 1C) revealing a clear core-shell structure. The TEM image shows that 
 
247 the core size of the hybrid  NPs ranged  from 80 to 120 nm, which is probably  due to 
 
248 the aggregation  of Cur@NaCas.  SEM  also demonstrated  the dimension  change  of 
 






























251 Figure  1. Transmission  electron  microscopy  (TEM)  (A,  B, and  C) and  scannmg 
 
252 electron microscopy (D, E, and F) and particle size distribution of native NaCas (A, 
 
253 D,  G),  Cur@NaCas  NPs  (B,  E,  G)  and  (Cur@NaCas)@CaP  NPs  (C,  F,   G).  G 
 
254 represent the particle size distribution of: native NaCas (black bars ranging from 22 to 
 
255 38 nm); Cur@NaCas (white  bars ranging  from 22 to 38 nm) the grey  bars (24 to  36 
 
256 nm) represent  the overlapping  particle size distribution  between  native NaCas   and 
 
257 Cur-in-NaCas ; and (Cur@NaCas)@CaP respectively (hatched bars ranging from 192 
 
258 to 208 nm). The blue boxed  area in (C) shows a high magnification  of this region by 
 




261 The formation of the CaP shell was further evidenced by XRD. The XRD patterns 
262 for  free  Cur  (a), NaCas  (b),  Cur@NaCas NPs (c), (Cur@NaCas)@CaP  NPs (d) and 
 
263 NaCas@CaP NPs (e) are shown in Figure  2A. The powder  diffraction  pattern of Cur 
 
264 displayed   several   sharp  peaks  at  diffraction   angles  of  8,   8.9,  14.5,  17.2,  21.1, 
 
265 suggesting  that  Cur  existed   in  a  crystalline  form.[35,  37]  Although  NaCas  was 
 
266 amorphous  lacking  crystalline  peaks (line  ' b'), some  minor evidence  of crystalline 
 
267 forms persisted in the Cur@NaCas NPs (line ' c' ). The minor crystalline signals might 
 
268 be due to fractions  of the entrapped  Cur protruding  from the NaCas casing, which  is 
 
269 likely  to  be  the  result  of  the  spontaneous  encapsulation  of  free  Cur  by  NaCas. 
 
270 Furthermore , the  characteristic  peak  of (Cur@NaCas)@CaP NPs and  NaCas@CaP 
 
271 NPs showed  the same  position  with the complete  absence  of any  diffraction   peak 
 
272 corresponding to Cur, indicating the formation of (Cur@NaCas)@CaP NPs where the 
 
273 NaCas@CaP core-shell formation completely shielded the encapsulated Cur. 
 
274 FT-IR spectroscopy was performed to verify the interaction between NPs and Cur, 
 
275 and also to confirm the mechanisms of encapsulation and surface coating.  The FT-IR 
 
276 spectra of free Cur (a), NaCas (b), Cur@NaCas NPs (c), (Cur@NaCas)@CaP  NPs (d) 
 
277 and  NaCas@CaP NPs (e) are shown in Figure 2B.  Cur was characterized  by discrete 
 
278 absorption peaks at 3502 cm-I  (phenolic O-H stretching,) 1720 cm-I  (C=O  stretching 
 
279 on the  diketone  groups), 1614  cm-1  and  1000  cm-1   (C=C  bending  on the aromatic 
 
280 rings),  1515  cm-1   (C=C  stretching  in aromatic  ring),  1450  cm-1   (C-H  bending on 
 
281 methyl   groups),  and   1300-1200   cm-1    (=C-O-CH3  stretching   of  alkyl-aryl  ether 
 
282 groups).  Most of the characteristic  peak of Cur  disappeared  after  encapsulation  by 
 
283 NaCas.[38]  For  NaCas,  the  characteristic  peaks  of  at  3424  cm-1  (free  O-H, N-H 
284 absorbing), 1644 (amide I group) shifted  to 3415 cm-1,  1628  cm-1  respectively  after 
 
285 self-assembling with Cur. These shifts are most likely due to the notion that hydrogen 
 
286 bonds  of NaCas  participated  in the formation  of Cur@NaCas  NPs, which involved 
 
287 changes  in the secondary  structure  of NaCas  proteins.l391 Furthermore, the peaks of 
 
288 (Cur@NaCas)@CaP NPs at 1123 cm-1,  1027 cm-1,  599 cm-1  and 559 cm-1  remained 
 
289 the  same  as  NaCas@CaP  NPs,  which  appeared   attributed   to  the antisymmetric 
 
290 stretching of PO4.[40] These results indicate that Ca3(PO4) 2 molecules were attached 
 
















293 Figure 2. (A) X-ray diffraction patterns and (B) Fourier-transform infrared spectra of 
 
294 the  Cur  (a),  NaCas  (b),  Cur@NaCas  NPs  (c),  (Cur@NaCas)@CaP  NPs  (d) and 
 




297 Zeta-potential was also used to confirm the loading of Cur and the formation of 
 
298 core-shell structure (Figure 3A). The zeta-potential values of NaCas decreased from - 
 
299 22.1  to -32.5  after  self-assembly  with Cur, indicating  an enhanced  anionic surface 
 














   
301 the number of less negatively charged K-casem and raise the number of high 
 
302 negatively  charged casein (asl -, as2-, -), which increased the overall magnitude of 
 
303 the  negative  zeta-potential.[41]  The  zeta  potential  of  CaP  was  -16.4  mV, which 
 
304 represents the  anionic  nature  of  CaP.  Following  entrapment  of  Cur@CaNas   by 
 
305 Ca3(PO4) 2,   the  zeta-potential of NPs  was  marginally  increased  to  -15.7 mV. This 
 
306 confirmed that the shielding by a CaP layer on the surface of Cur@NaCas altered the 
 
307 negative charge.[42] This higher zeta-potential of (Cur@NaCas)@CaP NPs would be 
 
308 beneficial  for its uptake into cells compared  with NaCas NPs  because  of the  lower 
 
309 electrostatic  repulsion,  relative  to  the  negatively  charged  surfaces  of cancer cells, 
 
310 which lowers the barrier to diffuse into cells.[43, 44] This hypothesis has been further 
 
311 investigated in subsequent experiments. 
 
312 Fluorescence spectrum was applied to study the intrinsic fluorescence of Cur as 
 
313 the microenvironment  changes  in aqueous  systems  (Figure  3B).  At  an excitation 
 
314 wavelength of 420 nm, Cur dissolved in ethanol showed the maximum light intensity 
 
315 at 535 nm, while Cur dispersed  in water almost without fluorescence.  The blue shift 
 
316 of  Cur  peak  at  535  nm,  to  517  nm  after  encapsulation  of  NaCas  NPs,  and the 
 
317 fluorescence intensity  increased  at the same time. It explained  that Cur was loaded 
 
318 into the  core of NaCas  by  hydrophobic  interactions,  which  provided   hydrophobic 
 
319 regions for Cur.[45] After the CaP coating, the blue shift of Cur peak from  517 nm to 
 
320 506.2 nm, and the further increased fluorescence intensity indicated that the surface of 
 


















323 Figure 3. (A) Average zeta-potential ofNPs. (B) Fluorescence emission spectra of 
 
324 Cur and NPs. 
 
 
325 3.2 Thermal and UV Stability of (Cur@NaCas)@CaP 
 
326 Thermal instability in aqueous solution is a major factor that limits Cur 
 
327 bioavailability.[46] This can be further confirmed in our experiment (Figure 4A). The 
 
328 rest of free Cur was 10.53 % after stored at 80 °C for 120 min, while 72.9 % of Cur 
 
329 remaining at  25  °C.  It  was  also  found  that  NaCas  encapsulation  only limitedly 
 
330 improved the  thermal  stability  of  Cur.  After  encapsulated  with  CaP  coating, the 
 
331 remaining Cur dramatically  reached  at 81.54 %  under  the same heating  treatment. 
 
332 Then, we studied  the degradation  kinetics  of free and  encapsulated  Cur in aqueous 
 
333 solution.   Both  free  and  NaCas  encapsulated   Cur  displayed   significantly  faster 
 
334 degradation at 80 °C than 25 °C (Figure 4B and Figure Sl ). After heated for 5 min at 
 
335 80 °C, more than 60 % of free Cur was lost. However, more than 99 % of Cur loaded 
 
336 in the NaCas@CaP NPs remained.  When the heating time reached  to 45 min, NaCas 
 
337 loaded Cur  showed  about  50 % of loss. In contrast, about  90 % of the NaCas@CaP 
338 loaded Cur remained. After heated for 120 min at 80 °C,  the aqueous solution of free 
 
339 and  NaCas loaded  Cur  became  transparent, and  their colors faded  (Seen the insert 
 
340 photos in Figure 4B). As reported, about 50 % of  soy protein isolate loaded Cur was 
 
341 inactivated  at 95 °C  within  30  mins,[12]  while  the  Cur encapsulated  by NaCas@CaP 
 
342 NPs didn ' t show sharp reduction within 2 h under high thermal condition. Thus, the 
 
343 above results indicated that CaP surface coating could efficiently protect the guest 
 
344 molecules from the thermal degradation. 
 
345 Cur also easily degraded under UV-light.[47] Stored in the UV-light conditions 
 
346 (Figure 4C), free Cur had a sharp degraded  by about 81.75 % after storage of 30 min 
 
347 and more than 90 % of free Cur degraded in 120 min. For NaCas NPs, almost 43 % of 
 
348 loaded Cur degraded  after 120 min. With CaP coating on the surface of NaCas, there 
 
349 was a partial degradation by 12 % in 30 min, and then maintained a certainly stability. 
 
350 Obviously, the shell of CaP provided  a superior  UV  protection of at least  1.4  folds 
 
351 than NaCas, and 8 folds better than free Cur. 
 
 




354 In practical applications the intend is not to retain the encapsulated compound 
 
355 indefinitely.  Instead ,  the  intend  would  be  to facilitate  protection  of the encapsulated 
 
356 compounds  prior to reaching  its target,  but then have a slow and  regular  release to 
 
357 limit the rate of physical applications. In this work, the in vitro release experiments of 
 
358 Cur@NaCas NPs and  (Cur@NaCas)@CaP NPs in different  PBS  buffer (pH 7.4 and 
359 5.5) were investigated and shown in Figure 4D. The whole release procedure lasted 
 
360 12 h, and Tween 80 (1% w/v) was added  to enhance the stability of Cur.[48] At both 
 
361 7.4 and  5.5,  more than 95 % of Cur  loaded  in NaCas NPs  was released within 4 h. 
 
362 Thus, a single protein  carrier consisting  of NaCas has the capability  of facilitating a 
 
363 pH-response  release, however, the relative  fast release  could  cause substantial drug 
 
364 leakage and inactivation. Previous studies have shown that CaP is  also a pH-sensitive 
 
365 material.[31, 49]  When encapsulated  in a NaCas@CaP hybrid  matrix, only  30 % of 
 
366 Cur  was  released  at 4  h in physiological  pH  (pH  7.4),  while  66.9  % of  Cur was 
 
367 released after 12 h at pH 7.4. By contrast, the cumulative release of Cur reached to 
 
368 99.8  %  after  12  h  at  pH  5.5  (Figure  4D).  Therefore,  the  pH-responsive  release 
 
369 behavior of NaCas@CaP NPs retards the premature drug release and subsequent rapid 
 
370 degradation/deactivation of the  drugs  after  administration,  and  achieves controlled 
 






























373 Figure 4. (A) In vitro stability of free Cur and Cur in the nanoparticles in water at pH 
 
374 7.4 upon storage in 120 min at 25 °C and 80 °C.(B) Degradation kinetics of free Cur 
 
375 and  Cur in  the NPs in water  at 80 °C from  up to 120 min  ,  and  the changes of free 
 
376 Cur(a and a')   ,  Cur@NaCas (band b') and (Cur@NaCas)@CaP (c and c' ) before and 
 
377 after heating  were shown in the picture.(C) Degradation  kinetics of free Cur and Cur 
 
378 in the NPs under  ultraviolet  light at 25 °C.(D)  Release  profiles of Cur@NaCas NPs 
 
379 and (Cur@NaCas)@CaP NPs at PBS (pH 7.4 and 5.5) in 12 h. 
 
 
380 3.4 Improved Cellular Uptake ofNaCas@CaP loaded Cur 
 
381 Confocal laser scanning microscopy (CLSM) was used to investigate whether 
 
382 encapsulated compounds have improved cellular uptake capacity. The CLSM images 
 
383 through   the  A549   monolayer cells  after  incubation with DMSO, free Cur, 
384 Cur@NaCas NPs, and (Cur@NaCas)@CaP NPs (all with equivalent  concentration of 
 
385 Cur) are shown in in Figure 5. The commercial  fluorescent dye propidium iodide (PI) 
 
386 was used  to characterize  cell morphology, and  the fluorescence  of Cur indicates the 
 
387 cell uptake  of  NPs.  (Cur@NaCas)@CaP  NPs  showed  stronger  green  fluorescent 
 
388 intensity  than an equal concentration  of free Cur and  NaCas loaded  Cur, suggesting 
 
389 NaCas@CaP NPs can improve the cellular uptake ability of encapsulated 
 
390 hydrophobic compounds. The reason for the lower green fluorescent  intensity for the 
 
391 Cur@NaCas NPs might  be due  to leakage  of Cur from  Cur@NaCas NPs.  Free Cur 
 
392 was shown to degrade rapidly and as such reduce its bioavailability at a slightly acidic 
 
393 cancer cell  environment   pH  (Figure   S2).   For  the  (Cur@NaCas)@CaP  NPs, the 
 
394 presence  of  a CaP  shell  increased  the  stability  of  Cur  in  a physiological aqueous 
 
395 environment  and  reduced  the cell  uptake  barriers  between NPs and Cur (Figure 5), 
 
396 thus evidencing improved cellular uptake and stability.[51 , 52] On the other hand, Cur 
 
397 would  be released  from  the NaCas  core  of the (Cur@NaCas)@CaP NPs  following 
 
398 cellular uptake.  It  is likely  that  any  intracellular  release  would  have  been  in part 
 
399 facilitated  by  endosomes  and  lysosomes,  and  achieved  a  cumulative  intracellular 
 
400 release.[53] Thus, the synergistic effect of shell and core increased the cell uptake 
 























403 Figure 5. Uptake of free Cur and encapsulated Cur into epithelial cells (A549, human 
 
404 alveolar  basal epithelial  cells) as observed  by confocal  laser  scanning microscopy 
 
405 (CLSM)  afte  4h of  exposure.  Column  ' PI' ,  Propidium  iodide  (PI)-only control; 
 
406 Column ' Cur', Cur-only  control; Column ' PI + Cur' , cells treated  with both PI  and 
 
407 Cur. (a) cells treated with DMSO; (b) cells treated with free Cur; (c) cells treated with 
 
408 Cur@NaCas NPs; and (d) cells treated with (Cur@NaCas)@CaP NPs 
 
 
409 3.5 Cellular Antioxidant Activity 
 
410 It has previously been shown that Cur has antioxidant activity and free radical 
 
411 scavenging  activities.[47] The cellular  anti-oxidant  activity  (CAA)  of free Cur and 
 
412 encapsulated  Cur were assessed  by the MGC-803 cell  model  (Figure  6A), and the 
 
413 anti-proliferation  activities  of  NPs  on  MGC-803  cells  are  shown  in  Figure  S3. 
 
414 According  to  the  principle  of  CAA,  peroxy   radicals  produced   by  ABAP cause 
 
415 oxidation  of DCFH  to form  the  fluorescent  DCF,  the DCF  fluorescence  intensity 
 
416 reflects  the  degree  of oxidation  damage  caused  by  free  radicals.[35]  The antioxidant 
417 capacity of any natural compounds  can be reflected  by the reduced DCF fluorescence 
 
418 intensity.  The results  (Figure  6A) indicated  that  DCF accumulated  continuously in 
 
419 the cells over time, while Cur could  quench  free radicals to reduce  the concentration 
 
420 of intracellular  DCF. The reduced  accumulation  of DCF demonstrates  that both the 
 
421 added   Cur@NaCas  NPs  and   (Cur@NaCas)@CaP   NPs   have  antioxidant activity, 
 
422 which  is  consistent   with  previous  work  that  reported   that  Cur  loaded inclusion 
 
423 complexes  possessed  a higher  free radical  scavenging  capacity  compared with free 
 
424 Cur.[54] The CAA value were determined  using eq.(3). The CAA results indicate that 
 
425 the NaCas and NaCas@CaP NPs loaded  Cur had  better cellular anti-oxidant activity 
 























428 Figure  6.  (A)  The  kinetics  curve  of  DCF  fluorescence  from  cellular anti-oxidant 
 
429 activity (CAA) of Cur, Cur@NaCas, (Cur@NaCas)@CaP, control, and  blank sample. 
430 In all instances the cells were exposed to equal amount of Cur. Error bars indicate the 
 
431 standard deviation following triplicate determinations. (B)The comparison of cellular 
 
432 anti-oxidant  activity  value  for different  samples.  (C) Anti-proliferation activity the 
 
433 blank  NPs toxicity  of human  alveolar  basal epithelial  cells (A549 cells).  (D) Anti- 
 
434 proliferation activity of 1, 5, 10 and 20 µg/mL DMSO-dissolved and encapsulated Cur 
 
435 against A549 cells. 
 
 
436 3.6 Cell Viability 
 
437 In order to investigate the cytotoxicity of (Cur@NaCas)@CaP NPs in cancer cells, 
 
438 we monitored the cell proliferation using human alveolar basal epithelial cancer  cells 
 
439 (A549  cells)  as a model.  The  native  NaCas  and  NaCas@CaP NPs  (without  Cur) 
 
440 showed  almost  100 % cell  viability  at 72 h (Figure  6C), indicating  that  the blank 
 
441 nanoparticle  was  nontoxic  and  biocompatible  with  the  cell  model  used  in  these 
 
442 experiments.[55] However,  with  Cur encapsulated  in either  NaCas  or NaCas@CaP 
 
443 NPs showed  an improved  anti-proliferation activity  against A549 cancer cells when 
 
444 compared with free Cur (Figure 6D). When the concentration of free Cur was applied 
 
445 at 1 µg/mL  and  5 µg/mL,  it  showed  a  mean  cell  viability  of  92.6 %  and  65.2 % 
 
446 respectively; while the Cur@NaCas inclusion  complex showed  a mean cell viability 
 
447 of 88.2 % and  56.6 % at 1 µg/mL  and  5 µg/mL of free  Cur  equivalent respectively. 
 
448 The (Cur@NaCas)@CaP inclusion  complex  did  not show the  same enhanced anti- 
 
449 proliferation effect on A549 cells compared to free Cur at the same Cur concentration, 
 
450 with a mean cell viability  of 98.8 % and 77.0 % at 1 µg/mL and 5 µg/mL of free  Cur 
451 equivalent  respectively.  A  more  prominent  improvement  in  the  anti- proliferation 
 
452 activity of NaCas@CaP loaded  Cur was observed  at an effective dose of free Cur 10 
 
453 µg/mL,  with a mean cell viability  of 13.5 %. At the same effective  Cur concentration, 
 
454 the cell viability of free Cur and Cur@NaCas NPs was 51.7 % and 34.0 %. It  appears 
 
455 that the anticancer  effect of NPs loaded  with Cur was related  to the release property 
 
456 and  biocompatibility of NPs, which is also relevant to the instability,  insolubility and 
 
457 concentration  of  Cur.[42,  56]  More  specifically,  when  considering  Cur  at a lower 
 
458 concentration,   the  release   rate  of   Cur  from   the  NPs   was  less than  the  rate  of 
 
459 deg radation, which resulted  in a lower  anti-cancer  activity  of the encapsulated Cur 
 
460 compared to free  Cur.  At the higher  concentration,  free  Cur  gradually  degraded in 
 
461 aqueous conditions in which the experiments were carried out, due to Cur' s instability 
 
462 and low biocompatibility; This while the chemical stability  of NPs loaded  Cur at the 
 
463 same equivalent concentrations was remarkably enhanced (Figure 6D). It  appears that 
 
464 the NaCas@CaP  loaded  Cur achieved  a more continuous  anti-cancer  effect,  which 
 
465 agrees with the CLSM results in this research (Figure 5). At the highest concentration 
 
466 tested  (20  µg/mL)  in  this  study,  the  cell  viability  of  A549  cells  exposed  to both 
 
467 Cur@NaCas  loaded  and  (Cur@NaCas)@CaP  loaded  NPs  was almost non-existent, 
 
468 while  the  addition  of  an  equivalent  concertation  of  free  Cur  saw  a  viability   of 
 
469 approximately 30%. This could  be ascribed  to the degradation  of free Cur under the 
 
470 experimental   conditions  where  some  of  the  added  free  Cur  might  have  already 
 
471 degraded  before  its full  weight  of  the  higher  concentration  could  affect  the cells 
472 (Figure S2), plus, it might have been possible that the higher concentration saturated 
 
473 the anti-proliferation effect against A549 cancer cells. 
 
 
474 4. Conclusions 
 
475 In conclusion, a novel hybrid nanodelivery system was prepared using NaCas and 
 
476 CaP. The nanosized NaCas@CaP NPs were shown to have an obvious core-shell 
 
477 structure, which markedly improved the stability of Cur under thermal conditions and 
 
478 UV  light conditions.  Besides,  the  pH-responsive  release  of Cur around  cancer cell 
 
479 environment was achieved. Furthermore, the results proved that NaCas@CaP NPs can 
 
480 improve anti-oxidant activity, cell uptake ability and anti-proliferative activity of Cur 
 
481 in  living   cells.  Our  research   provided   a  simple  and   stable  nano-platform   for 
 
482 encapsulating sensitive hydrophobic biomolecules. The results revealed that this core- 
 
483 shell  nanodelivery   system  was  meaningful  for  keeping  bioactivities  of sensitive 
 
484 molecules  and  improving the bioavailability in cancer treatment. Thus, this 
 
485 nanodelivery system is expected to be applied for in food and pharmaceutical 
 
486 products field. 
 
487 For human health and practical application , further research is still undergoing in 
 
488 our  laboratory   including   the  delivery   behavior  and  uptake  mechanism   of  this 
 
489 nanodelivery system in various food and animals' systems, as well as the bioactivities 
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Table S1 Effect of NaCas concentration on drug loading efficiency (DLE) (%). 
 
 
NaCas (mg/mL) Cur (mg/mL) Stirring speed (rpm/min) Stirring time (h) DLE (%) 
0.5 0.5 600 1.5 62.34±1.30 
0.75 0.5 600 1.5 78.67±1.14 
1 0.5 600 1.5 80.63±1.37 
1.25 0.5 600 1.5 80.94±1.43 
1.5 0.5 600 1.5 81.13±1.29 
All samples were prepared at room temperature. 
 
 
Table S2 Effect of stirring speed on DLE (%) 
 
 
NaCas (mg/mL) Cur (mg/mL) Stirring speed (rpm/min) Stirring time (h) DLE (%) 
1 0.5 400 1.5 57.83±1.17 
1 0.5 500 1.5 63.49±1.23 
1 0.5 600 1.5 80.98±1.27 
1 0.5 700 1.5 84.24±1.31 
1 0.5 800 1.5 84.32±1.43 





Table S3 Effect of stirring time on DLE (%) 
 
 
NaCas (mg/mL) Cur (mg/mL) Stirring speed (rpm/min) Stirring time (h) DLE (%) 
1 0.5 700 0.5 50.64±1.34 
1 0.5 700 1.0 73.68±1.49 
1 0.5 700 1.5 84.97±1.38 
1 0.5 700 2.0 90.01±1.29 
1 0.5 700 2.5 90.27±1.44 
All samples were prepared at room temperature. 
 
Table S4 Effect of the added CaP volume on DLE (%) 
 
 
CaP concentration (mM) CaP volume (µL) Mixing time (min) DLE (%) 
50 5 2 21.57±2.06 
50 10 2 53.24±1.92 
50 15 2 80.42±2.14 
50 20 2 99.25±1.97 
50 25 2 99.47±2.03 
All samples were prepared at room temperature. 
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Figure S1 Degradation kinetics of free Cur and Cur in the NPs in water from up 
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Figure S3 Anti-proliferation activity of 1, 2, 3, 4 and 5 µg/mL DMSO-dissolved 
and encapsulated Cur against MGC-803 cells, and treatment for 24 h. 
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